Two Sigma Advisers
SRRA

Two Sigma Advisers’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

Two Sigma Advisers’s Portfolio SRRA Stock Details SRRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-189,156
Closed -$10.4M – 2843
2022
Q2 		$10.4M Sell
189,156
-67,400
-26% -$3.54M 0.03% 493
2022
Q1 		$8.22M Buy
256,556
+194,800
+315% +$5.59M 0.02% 597
2021
Q4 		$1.34M Buy
61,756
+19,100
+45% +$421K ﹤0.01% 1396
2021
Q3 		$935K Buy
+42,656
New +$853K ﹤0.01% 1647
2020
Q1 		– Sell
-3,693
Closed -$51K – 2612
2019
Q4 		$51K Sell
3,693
-277
-7% -$3.61K ﹤0.01% 2292
2019
Q3 		$62K Buy
3,970
+2,182
+122% +$41.8K ﹤0.01% 2143
2019
Q2 		$40K Buy
1,788
+890
+99% +$43.1K ﹤0.01% 2263
2019
Q1 		$61K Buy
898
+310
+53% +$19.9K ﹤0.01% 2223
2018
Q4 		$31K Sell
588
-447
-43% -$28.5K ﹤0.01% 2303
2018
Q3 		$70K Buy
1,035
+20
+2% +$1.81K ﹤0.01% 2163
2018
Q2 		$120K Buy
+1,015
New +$102K ﹤0.01% 2259
2018
Q1 		– Sell
-290
Closed -$43K – 2460
2017
Q4 		$43K Buy
+290
New +$27.9K ﹤0.01% 2201

Other funds holding SRRA

HI
Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Two Sigma Advisers's SRRA Position: Q3 2022 in Review

Two Sigma Advisers sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q3 2022, closing a stake of 189,156 shares — an estimated $10.4M sold.

Two Sigma Advisers first reported a position in SRRA in Q4 2017 and held it in 12 quarters. The position peaked at $10.4M in Q2 2022. 1 fund tracked by Wall St. Rank holds SRRA as of Q3 2022.

  • Two Sigma Advisers reported no remaining Sierra Oncology, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Two Sigma Advisers sold 189,156 Sierra Oncology, Inc. Common Stock shares in Q3 2022, an estimated $10.4M.
  • Two Sigma Advisers first reported a position in Sierra Oncology, Inc. Common Stock in Q4 2017 and held it in 12 quarters.
  • Two Sigma Advisers's Sierra Oncology, Inc. Common Stock position peaked at $10.4M in Q2 2022.
  • 1 fund tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q3 2022.

Based on Two Sigma Advisers's 13F filing for Q3 2022, filed 14 Nov 2022.